Alnylam Pharma (ALNY) Tops Q4 EPS by 49c; offers guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $291.37 -0.61%
EPS Growth %: +409.4%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
CGEH, NAKA, APOG, More
EPS Growth %: +409.4%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($0.77), $0.49 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $346.29 million versus the consensus estimate of $436.08 million.
GUIDANCE:
Alnylam Pharma sees FY2024 revenue of $1400-1500 million, versus the consensus of $1770 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
- MakeMyTrip (MMYT) PT Raised to $84 at Goldman Sachs
- KeyBanc lowers Nike rating to Sector Weight on near-term uncertainty
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
